Factors influencing Patient Preferences for BRCA Testing and Adjuvant Therapy in HER2-Negative Early Breast Cancer in the United States: Best–Worst Scaling and Discrete Choice Experiment
Individuals reported that a key benefit of BRCA testing was the insight it provided into their treatment options, allowing for more personalized care. However, OOPC was a barrier to testing. Their choice to receive adjuvant therapy was most influenced by OOPC, followed by the tolerability of the treatment and the ability to receive a targeted therapy.
Authors
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Kim M. Hirshfield (ORCID: https://orcid.org/0000-0002-5848-1316)
- Kathryn Mishkin (ORCID: https://orcid.org/0000-0003-0050-8106)
- Kathryn L. Krupsky (ORCID: https://orcid.org/0000-0001-8793-6861)
- Jagadeswara Rao Earla (ORCID: https://orcid.org/0000-0002-6688-5273)
- Josh Lankin
- Jaime Mejia (ORCID: https://orcid.org/0000-0002-1315-6878)
- Ryan Honomichl (ORCID: https://orcid.org/0000-0002-0535-4268)
- Xiaoqing Xu (ORCID: https://orcid.org/0000-0001-8209-6963)
- Qixin Li (ORCID: https://orcid.org/0009-0006-9752-4696)
- Emily Mulvihill (ORCID: https://orcid.org/0000-0002-1430-8837)
- Alexandra Gordon (ORCID: https://orcid.org/0009-0003-5163-8119)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oracle (United States) (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Patient
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1007/s40271-025-00783-1
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca